Nurix Therapeutics
NRIX
Nurix Therapeutics (NRIX) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- May 31, 2025
- EPS actual
- −$0.52
- EPS estimate
- −$0.72
- EPS surprise
- +27.65%
- Revenue surprise
- +151.08%
- Revenue
- $44.1M
- Revenue estimate
- $17.5M
- Reported
- Jul 9, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Jul 9, 2025 | −$0.72 | −$0.52 | +27.65% | $44.1M | SEC |
| Q1 2025 | Apr 8, 2025 | −$0.76 | −$0.67 | +12.06% | $18.5M | SEC |
| Q4 2024 | Jan 28, 2025 | −$0.69 | −$0.75 | −9.31% | $13.3M | SEC |
| Q3 2024 | Oct 11, 2024 | −$0.69 | −$0.67 | +2.57% | $12.6M | SEC |
| Q2 2024 | Jul 11, 2024 | −$0.63 | −$0.71 | −11.85% | $12.1M | SEC |
| Q1 2024 | Apr 10, 2024 | −$0.78 | −$0.76 | +2.01% | $16.6M | SEC |
| Q4 2023 | Feb 15, 2024 | −$0.50 | −$0.77 | −55.12% | $15.2M | SEC |
| Q3 2023 | Oct 12, 2023 | −$0.84 | −$0.68 | +18.90% | $18.5M | SEC |
| Q2 2023 | Jul 13, 2023 | −$0.57 | −$0.45 | +20.68% | $30.7M | SEC |
| Q1 2023 | Apr 13, 2023 | −$0.87 | −$0.75 | +13.52% | $12.7M | SEC |
| Q4 2022 | Feb 9, 2023 | −$0.78 | −$0.87 | −11.11% | $6.8M | SEC |
| Q3 2022 | Oct 6, 2022 | −$0.95 | −$0.90 | +5.05% | $10.8M | SEC |
| Q2 2022 | Jul 7, 2022 | −$0.97 | −$1.01 | −3.98% | $11.4M | SEC |
| Q1 2022 | Apr 7, 2022 | −$0.88 | −$0.95 | −8.48% | $9.6M | SEC |
| Q4 2021 | Jan 27, 2022 | −$0.68 | −$0.85 | −24.54% | $7.4M | SEC |
| Q3 2021 | Oct 14, 2021 | −$0.62 | −$0.65 | −4.60% | $10.3M | SEC |
| Q2 2021 | Jul 13, 2021 | −$0.54 | −$0.60 | −12.15% | $7.1M | SEC |
| Q1 2021 | Apr 13, 2021 | −$0.45 | −$0.63 | −39.23% | $5.0M | SEC |
| Q4 2020 | Feb 16, 2021 | −$0.53 | −$0.51 | +4.49% | $6.7M | SEC |
| Q3 2020 | Oct 14, 2020 | −$0.41 | −$0.59 | −43.03% | $4.1M | SEC |
Quarterly revenue
Frequently asked questions
When did Nurix Therapeutics (NRIX) last report earnings?
Nurix Therapeutics last reported on Jul 9, 2025, covering fiscal Q2 2025.
Did NRIX beat earnings estimates?
Yes. Nurix Therapeutics reported EPS of −$0.52 for Q2 2025 against a −$0.72 estimate — a 27.65% beat.
How much revenue did NRIX report last quarter?
Nurix Therapeutics reported $44.1M in revenue for Q2 2025, against a consensus estimate of $17.5M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.